Atea Pharmaceuticals

• The FDA updated safety information for obeticholic acid (Ocaliva) regarding liver injury risk in primary biliary cholangitis (PBC) patients without cirrhosis. • Breakthrough Therapy designation was granted to tobevibart and elebsiran by the FDA and EMA for chronic hepatitis delta (CHD) treatment, based on Phase 2 SOLSTICE trial data. • Atea Pharmaceuticals reported positive Phase 2 results for bemnifosbuvir and ruzasvir in hepatitis C virus (HCV) treatment, achieving a 98% SVR12 rate. • Belapectin, from Galectin Therapeutics, in MASH cirrhosis and portal hypertension, did not meet its primary endpoint in the Phase 2b/3 NAVIGATE trial.

• Mayo Clinic Arizona found removing _C. difficile_ from gastrointestinal pathogen panels reduced unnecessary treatments and improved diagnostic stewardship. • A _Salmonella_ outbreak linked to cucumbers has sickened 68 people across 19 US states, leading to a product recall by SunFed Produce LLC. • Atea Pharmaceuticals' combination therapy for hepatitis C achieved a 98% SVR12 rate in a Phase 2 trial, paving the way for Phase 3 studies. • Gilead's lenacapavir injection demonstrated high efficacy in preventing HIV infection in Phase 3 trials, leading to NDA submission.

Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for hepatitis C met its primary endpoint, demonstrating a 98% SVR12 rate in treatment-adherent patients.

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 treatment did not meet its primary endpoint of reducing all-cause hospitalization or death.